本发明提供了的特异性双靶向抗体(bispecificantibody,bsab),能够同时与cd3和gpc3抗原结合;特异地识别并结合gpc3抗原阳性细胞,同时也结合表达cd3的t细胞,可在t细胞与肿瘤细胞之间形成免疫突触(immunesynapse),发挥t细胞受体(tcellreceptor,tcr)一样的功能,从而激活t细胞免疫机制,介导t细胞发挥杀伤gpc3阳性肿瘤细胞的作用,从而...
GPC3-Unc5 receptor complex structure and role in cell migration. PMID: 36240740 CD3E immune restorative ability induced by Maitake Pro4x in immunosupressed BALBc mice. PMID: 36138418 Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon ...
CM350是基于康诺亚专有nTCE双特异性抗体平台开发的一款GPC3xCD3双特异性抗体。CM350通过同时靶向肿瘤细胞的GPC3及T细胞的CD3，激活T细胞并将其重定向至靶向肿瘤细胞，从而完成肿瘤细胞的清除，目前针对的适应症为实体瘤，尤其是肝细胞癌。CM350 现处于Ⅰ期临床的剂量递增阶段。3.2 CAR-T疗法 BOXR1030 BOXR1030是由...
GPC3-Unc5 receptor complex structure and role in cell migration. PMID: 36240740 CD3E immune restorative ability induced by Maitake Pro4x in immunosupressed BALBc mice. PMID: 36138418 Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon ...
GPC3-Unc5 receptor complex structure and role in cell migration. PMID: 36240740 CD3E immune restorative ability induced by Maitake Pro4x in immunosupressed BALBc mice. PMID: 36138418 Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon ...
0.81μg/kg剂量被证实不耐受,T细胞CD3的激活可能诱导“细胞因子风暴”的风险,另外ERY974保留FC端,分子量较大,组织穿透力被削弱。GPC3/CD47是一种靶向GPC3和CD47的双特异性抗体,通过识别这两种抗原可有效抑制肿瘤生长。与单独的抗CD47抗体相比,该抗体具有较长的血清半衰期。在小鼠异种移植模型中,GPC3/CD47双抗比单药...
8. Du K, Li Y, Liu J, et al. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC. Mol Ther. 2021;29(4):1572-1584. doi:10.1016/j.ymthe.2021.01.006. 9. Wu X, Luo H, Shi B, et al. Combined Antitumor Effects of Sora...
The GPC3-specific CAR in this study was based on the humanized GPC3-specific antibody hu9F2 that we developed and the CD28 and CD3ζ signaling domains. The NK-92 cells transduced with GPC3-specific CAR were enriched and designated NK-92/9.28.z cells. In this study, we mainly determined ...
Abstract CT111: Results of a phase 1 dose escalation study of ERY974, an anti-glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tu... We have previously shown that the reexpression of Glypican-3 (GPC3), a proteoglycan downregulated in breast cancer, leads to the ...